BPG is committed to discovery and dissemination of knowledge
Citation
Liu Chen Kiow J, Hoang T, Bedi HK, Majdzadeh Ardekani Z, Rosenfeld D, Reise-Filteau M, Bressler B, Leung Y, Rosenfeld G. Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel disease. World J Gastroenterol 2024; 30(46): 4904-4913 [PMID: 39679312 DOI: 10.3748/wjg.v30.i46.4904]
Please LOGIN to submit a new comment.